Apr
25,
2021

Lallemand Pharma launches its new range of Medical Devices « Healsea® »

Apr 25, 2021

Lallemand Pharma launches its new range of products Healsea®, completing its portfolio of products dedicated to the respiratory tract affections, till now only dedicated to Ismigen®. This new range of products has been developed on the basis of the association of sea water or saline solution with Symbiofilm®, an exopolymeric substance that inhibits the development of pathogenic bacteria biofilm and the adhesion of respiratory viruses to the nasal mucosa. Symbiofilm® is a postbiotic derived from the fermentation of our marine bacteria Bacillus licheniformis  Lallemand Pharma T14.

The range of Medical Device (MD) Healsea® is proposed in 2 classes (Class I manual pump & Class IIa bag on valve technology) containing several formulas Protect, Rescue, Chronic, Children.